National Framework Agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders
Awarded by NHS England · to Baxalta Limited · 2017-11-24T00:00:00Z · £302,000,000
Description
NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders. The framework will commence on 1.2.2018 for a period of 12 months until 31.1.2019 with options to extend up to a further 17 months.
- Supplier
- Baxalta Limited
- Buyer
- NHS England
- Value
- £302,000,000
- Category (CPV)
- Blood coagulants
- Award date
- 2017-11-24T00:00:00Z
- Buyer constituency
- runcorn-and-helsby
Full CPV hierarchy, related awards from the same supplier and buyer, and any declared MP interest overlaps load below when JavaScript is enabled.